Cell and gene therapies (CGTs) are redefining what is possible in modern medicine, offering innovative and potentially curative treatments for diseases that were once considered untreatable. Scientific innovation across adeno-associated virus (AAV), lentivirus (LV) and retrovirus (RV) viral vectors has accelerated rapidly, driving a growing and increasingly diverse clinical pipeline.
While science and CGT innovation have moved quickly, manufacturing often still remains a critical rate-limiting step. High-quality viral vectors are the backbone of CGTs, and the ability to scale their production reliably, reproducibly and compliantly is key to determining how quickly and efficiently a promising therapy reaches patients.
Scaling a viral vector from early research to good manufacturing practice (GMP) production is a multi-step journey that transforms innovative science into viable, commercial-ready processes and products. From plasmid sourcing to analytical design, each decision made along the way creates either friction or momentum for the future. The most successful CGT programmes are those that start with the end in mind, building scalability, quality and regulatory confidence into development from the outset.
This article explores the key stages of viral vector scale-up and examines how early technical and strategic choices can strengthen quality, protect timelines and set the foundation for long-term success.
Viral Vector Challenges and Opportunities The CGT sector is maturing with a growing number of approved therapies, alongside a surge in clinical programmes targeting both rare and more prevalent diseases. As of the end of 2025, 38 gene therapies, 36 RNA therapies and 71 non-genetically modified cell therapies have been approved globally for clinical use. This reflects increasing regulatory confidence and technical progress. For small and mid-sized biotechs, this momentum presents a significant opportunity but also new operational pressures.
Viral vectors sit at the heart of the challenges associated with CGT development and manufacturing but also offer the potential for strategic opportunities. Demand for AAV, LV and RV vectors continues to rise across therapeutic areas such as oncology, neurology and rare genetic disorders. Although all the vector types share common manufacturing processes, each specific type has its own set of unique challenges. Developers must also navigate increasingly complex expectations around manufacturing consistency, analytical rigor and GMP compliance.
The viral vector manufacturing landscape has evolved to meet this demand. Contract development and manufacturing organisations (CDMOs) now offer end-to-end services and advances in platform processes and analytics are improving yields and reproducibility while helping reduce the cost of goods. However, this expansion has been uneven. Industry consolidation is accelerating, with some CDMOs narrowing their focus or exiting viral vectors entirely, and commercial-scale experience remaining limited.
For emerging and mid-size biotechs with finite resources and tight financial budgets, selecting the right manufacturing partner has become as strategically important as the science itself. Capacity alone is no longer enough. Partners must be able to translate early innovation into scalable, commercial-ready manufacturing.
